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Depression and schizophrenia cause severe impairments in social
functioning and rank among the leading mental health causes of
the global burden of disease.1,2 Impairment of social functioning,
defined as ‘an individual’s ability to perform and fulfil normal
social roles’,3 is a major reason for the high levels of stigma and
disability associated with these mental disorders. Although there
have been numerous reviews of the clinical effectiveness of
interventions for mental disorders,4–7 the effect of psychosocial
interventions on social functioning has not been reviewed. Only
17 of the 62 Cochrane reviews of psychosocial interventions to
treat depression or schizophrenia include social functioning
outcomes, with only a tiny fraction of the included trials from
low- and middle-income (LAMI) countries (the results of these
reviews are summarised in online Table DS1). This review aims
to synthesise all randomised controlled trials (RCTs) conducted
in LAMI countries evaluating the effectiveness of psychosocial
interventions to treat depression or schizophrenia on social
functioning outcomes.
Method
The methods and results in this paper are presented according to
the PRISMA statement for reporting systematic reviews.8
Selection of studies
A protocol for the review was developed in collaboration with a
Cochrane information scientist. The Appendix lists the inclusion
and exclusion criteria for the review. In summary, the review
included all RCTs that assessed the effect of psychosocial
interventions on the social functioning of people living with
depressive disorders or schizophrenia in LAMI countries.
Psychosocial interventions were defined broadly as any non-
pharmacological or physical intervention,9 and comprised
structured psychotherapies such as cognitive–behavioural therapy
(CBT); psychosocial interventions such as social skills training;
alternative therapies including exercise and art therapy; and
collaborative care stepped-care interventions that combine a series
of different interventions. Trials were included as long as they
compared the intervention group with a control group receiving
a placebo or treatment as usual (TAU). This ensured that the
effectiveness of the intervention was assessed, rather than its
equivalence to a similar treatment.
To be included, trials must have quantitatively assessed the
effect of the intervention on patient social functioning, measured
using a validated tool. Social functioning can be seen as one aspect
of disability comprising social and physical functioning, both
subdomains of quality of life.10 Core domains include:
occupation, education, household role, marital functioning,
parental role, leisure and recreational activities and self-care,11 as
well as an individuals’ satisfaction with their ability to meet these
roles.12 Because social functioning is a subdomain of quality of
life,10 quality of life measures were excluded from the review.
Equally, scales reporting general health status (such as the Short
Form 36-item questionnaire (SF-36)13) were excluded, although
studies that reported the results of the social functioning subscale
of general health scales were included. Where studies included
more than one measure of social functioning, results for the scale
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Background
Psychosocial interventions may contribute to reducing the
burden of mental disorders in low- and middle-income (LAMI)
countries by improving social functioning, but the evidence
has not been systematically reviewed.
Aims
Systematic review and meta-analysis of the effect of
psychosocial interventions on social functioning in people
with depression and schizophrenia in LAMI countries.
Method
Studies were identified through database searching up to
March 2011. Randomised controlled trials were included if
they compared the intervention group with a control group
receiving placebo or treatment as usual. Random effects
meta-analyses were performed separately for depressive
disorders and schizophrenia and for each intervention type.
Results
Of the studies that met the inclusion criteria (n=24), 21 had
sufficient data to include in the meta-analysis. Eleven
depression trials showed good evidence for a moderate
positive effect of psychosocial interventions on social
functioning (standardised mean difference (SMD) = 0.46, 95%
CI 0.24–0.69, n=4009) and ten schizophrenia trials showed
a large positive effect on social functioning (SMD=0.84,
95% CI 0.49–1.19, n=1671), although seven of these trials
were of low quality. Excluding these did not substantially
affect the size or direction of effect, although the precision
of the estimate was substantially reduced (SMD=0.89,
95% CI 0.05–1.72, n=863).
Conclusions
Psychosocial interventions delivered in out-patient and
primary care settings are effective at improving social
functioning in people with depression and should be
incorporated into efforts to scale up services. For
schizophrenia there is an absence of evidence from
high-quality trials and the generalisabilty of the findings
is limited by the over-representation of trials conducted in
populations of hospital patients in China. More high-quality
trials of psychosocial interventions for schizophrenia
delivered in out-patient settings are needed.
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that captured the most domains of social functioning were
extracted.
The search was not restricted by date, language or publication
status. The following electronic databases were searched: Medline,
PsycINFO, Cochrane Central, Econlit and ISI Web of Science
using Medical Subject Heading (MeSH) terms (or equivalent
terms) for published peer-reviewed journal articles. The online
supplement lists the full search strategy. Randomised controlled
trials for all mental disorders were searched, and those relating
to depression and schizophrenia manually selected. The last search
was conducted in March 2011. The reference lists of all selected
papers were screened and authors of relevant studies contacted
to seek additional studies and request information not present
in the published paper.
Initial screening of irrelevant abstracts involved one author
(M.J.D.S.) searching through the database of search results for
papers that were not related to mental health. Two authors
(M.J.D.S. and S.C.) then independently screened the titles and
abstracts of the remaining search results and the full text copies
of all potentially relevant studies to determine whether they met
the pre-specified inclusion criteria. Disagreements were resolved
by discussion among all authors.
Data were extracted by two authors using a standard data
extraction form including inclusion criteria for participants,
intervention and control groups, outcome measures and effect
estimates. The quality of included studies was assessed using the
Cochrane risk of bias tool14 by two authors. Risk of bias was
assessed both at the study level (for example sequence generation
and allocation concealment) and at the outcome level (for
example losses to follow-up for the social functioning outcome).
Data for the meta-analyses were extracted by H.L.L. and double
checked by M.J.D.S. Where trials reported more than one
follow-up time point, data were extracted from the closest time
point to 6 months for depression trials and 12 months for
schizophrenia trials. These time points were chosen to reflect
the longer-term effect that psychosocial interventions are
anticipated to have on social functioning outcomes.
Data analysis
Statistical analyses were performed using Review Manager 5 for
Windows 7. The post-treatment mean and standard deviation
(s.d.) of the social functioning score in the intervention and
control group were extracted along with the sample size in each
group to calculate the standardised mean difference (SMD) for
each trial to enable different outcome scales to be pooled. Where
cluster RCTs were included, the mean post-treatment scores
calculated from an appropriate analysis adjusted for clustering
were used to enable them to be combined with the results of
individually randomised trials.15 To correct for differences in the
direction of the scales (for example some scales increase with
increasing severity and others decrease), the mean values from one
set of studies was multiplied by 71 to ensure that all the scales
point in the same direction. Acknowledging the heterogeneity in
interventions and study design, random effects meta-analyses were
performed separately for depressive disorders and schizophrenia
and within this separately for each intervention type. The I 2
statistic was used to assess heterogeneity between trials.
A number of sensitivity analyses were conducted. To control
for study quality, trials that had a risk of bias for allocation
concealment, or for whom allocation concealment could not be
assessed but who had a risk of bias for sequence generation and/
or masking of outcome assessment, were excluded from the
meta-analysis. Separate meta-analyses were conducted to assess
the long- and short-term effects on social functioning. Short-term
follow-up was defined as less than 6 months for depressive
disorders and less than 12 months for schizophrenia, and long-
term follow-up as more than 6 months for depression and more
than 12 months for schizophrenia. We contacted the authors for
missing data necessary for the meta-analysis. Where these data
were not available we conducted a sensitivity analysis to exclude
those studies with a high risk of bias, including those with bias
due to missing data for their outcome assessment. We did not
impute missing data as we were unable to obtain the raw data
from authors. Lastly, funnel plots for the primary meta-analyses
were generated to assess possible publication bias.
Results
Figure 1 presents the search and selection process for the review. A
total of 9592 unique records were obtained, of which 24 trials met
the inclusion criteria. Thirteen papers were in English, ten in
Chinese and one in Spanish.
Measurement of social functioning
Online Table DS2 lists the social functioning tools used by the
included trials. The 24 included trials used 10 different scales to
measure social functioning, confirming the previously reported
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Fig. 1 Selection of studies.
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lack of consensus on its measurement.16 Seven of the included
tools were patient self-assessments, and three were clinician-rated.
Half were developed to measure social functioning in a psychiatric
population, and four specifically for populations in LAMI
countries. Many of the tools were sophisticated in their
measurement of a number of domains of social functioning,
although no tool measured all domains, and had been
appropriately validated in either a number of populations, or
specifically in the population in which they were used. Table 1
summarises the trials included in the review separately for
depression and schizophrenia.
Effect of psychosocial interventions to treat
depression
In total 11 trials assessed the effect of interventions to treat
depression, 6 assessed multicomponent collaborative care inter-
ventions, three interpersonal therapy (IPT), 1 problem-solving
therapy, and 1 Morita therapy. Four of the trials were from Chile,
three from China, and the remainder from India, Brazil and
Uganda. The majority of trials were set in out-patient, primary
care or community settings. Five of the trials used non-mental
health specialists to deliver the intervention through task-sharing.
Only one trial was assessed as having an overall risk of bias and
nine had long-term follow-up of more than 6 months. Figure 2
presents the forest plot for the main results meta-analysis with
follow-up clustered around 6 months. Online Table DS3 reports
the characteristics and main findings of the depression trials and
online Figs DS1–3 presents the forest plots for the sensitivity
analyses.
All 11 depression trials were suitable for inclusion in the meta-
analysis. The combined SMD for all interventions was 0.46 (95%
CI 0.24–0.69, P40.001, I 2 = 90%, n=4009), indicating small to
moderate improvements in social functioning based on the rule
of thumb interpretation of SMDs whereby 0.2 represents a small
effect, 0.5 a moderate effect and 0.8 a large effect.29 Excluding
the one trial with a risk of bias did not affect this conclusion,
and the magnitude of effect was the same for both short- and
long-term follow-up.
There was robust evidence from the six trials evaluating
multicomponent interventions for a small improvement in social
functioning (SMD=0.35, 95% CI 0.11–0.59, P40.001, I 2 = 89%,
n= 3291). These multicomponent interventions involved
structured pharmacotherapy, psychoeducation, adherence support
and in some cases IPT or cognitive trauma-based therapy. These
interventions were often delivered by non-specialist health
workers as part of a multidisciplinary team in a stepped-care
model. The control arm received TAU, which frequently included
access to pharmacotherapy or psychological therapy if indicated.
There was evidence from three trials of a large, positive impact
of IPT on social functioning (SMD=0.84, 95% CI 0.40–1.29,
P= 0.0002, I 2 = 67%, n= 360). Two trials examined the effect of
group IPT delivered in 1220 or 1618 sessions and the third assessed
the impact of 16 sessions of individual IPT.19 There was not
enough evidence to assess the effect of problem-solving therapy
or Morita therapy as only one trial respectively assessed these
interventions.
Effect of psychosocial interventions to treat
schizophrenia
Thirteen trials assessed the effect of interventions to treat schizo-
phrenia: 3 trials assessed the effect of family psychoeducation, 1
patient psychoeducation, 1 social skills training, 1 art therapy,
4 multicomponent structured psychotherapies and 3 community-
based care interventions. In contrast to the depression trials, most
(11/13) were conducted in China in hospital in-patient
populations and only two used non-specialists to deliver the
intervention. No trials were included from Sub-Saharan Africa
or South Asia. Seven were assessed as having a risk of bias and five
had strict inclusion criteria limiting the generalisability of the
results. Three trials did not contain sufficient data to be included
in the meta-analysis,30–32 and as we were unable to obtain this
information from the authors, these trials are included in the
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Table 1 Summary characteristics of studies included in the review
Depression studies, n
(n=11)
Schizophrenia studies, n
(n=13) Total, n
Country
Chile 4 0 4
Brazil 1 1 2
China 3 11 14
India 2 0 2
Uganda 1 0 1
Turkey 0 1 1
Setting
Hospital in-patient 2 7 9
Hospital out-patient 4 4 8
Primary healthcare 4 0 4
Community 1 2 3
Intervention
Psychological therapy 4 9 13
Other interventiona 1 1 2
Multicomponent collaborative care 6 3 9
Intervention delivered by non-mental health specialist 5 2 7
Study design
Long-term follow-upb 9 6 15
Strict inclusion criteria 4 5 9
Small sample size (550 participants per arm) 3 8 11
Assessed as overall high risk of bias 1 7 8
a. Morita therapy and art therapy.
b. Long-term follow-up defined as more than 6 months from the start of the intervention for depression, and more than 12 months for schizophrenia.
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qualitative synthesis of results only. Figure 3 presents the forest
plot for the main results meta-analysis with follow-up clustered
around 12 months. Online Table DS4 reports the characteristics
and main findings of the schizophrenia trials. Online Figs DS4–6
presents the forest plots for the sensitivity analysis.
The combined SMD for all interventions was 0.84 (95% CI
0.49–1.19, P40.001, I 2 = 89%, n= 1671), indicating large
improvements in social functioning. Excluding the seven trials
with a risk of bias did not substantially affect the size or direction
of effect, although the precision of the estimate was substantially
reduced due to the smaller pooled sample sizes (SMD=0.89,
95% CI 0.05–1.72, P40.001, I 2 = 91%, n= 863). The effect of
the interventions on social functioning increased over time, with
moderate effect sizes at less than 12 months’ follow-up
(SMD=0.71, 95% CI 0.36–1.06, P40.001, I 2 = 88%, n= 1718),
increasing to a large effect on social functioning at more than
12 months’ follow-up (SMD=0.93, 95% CI 0.37–1.49, P40.001,
I 2 = 95%, n=1409). However, the risk of bias associated with
seven of these ten studies limits the strength of the evidence from
this meta-analysis.
There was good evidence from four trials of large improve-
ments in social functioning due to multicomponent structured
psychotherapies against TAU with both groups receiving anti-
psychotic medication36–39 (SMD=0.93, 95% CI 0.23–1.63,
P40.0001, I 2 = 89%, n= 893). All trials included psychoeducation
supplemented with at least two additional therapies comprising
skills training, CBT, IPT and family therapy. Three of these trials
had a low risk of bias and a sensitivity analysis restricted to these
trials did not affect this finding.
There was weak evidence from three poor-quality trials of a
large positive effect of psychoeducation on social functioning
(SMD=1.15, 95% CI 0.06–2.25, P40.001, I 2 = 95%, n= 362).
Two of these trials assessed the impact of family psycho-
education,33,34 and one patient psychoeducation35 compared
with TAU, with both groups receiving antipsychotic medication.
The meta-analysis was skewed by the study of individual patient
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Heterogeneity: not applicable
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Fig. 2 Depression: all studies (6-month follow-up).
Patel et al (2011): a. recruited from public primary healthcare clinics, b. Recruited from private general practice clinics.
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psychoeducation, which had a much larger effect than the two
family interventions. A fourth trial on family psychoeducation
that could not be included in the meta-analysis also reported a
significant positive effect on social functioning.30 As four trials
were assessed as having a high overall risk of bias (two because
the risk of bias was unknown due to lack of information in the
published paper), the level of evidence for psychoeducation is
currently weak.
There was weak evidence from two trials with a high risk of
bias41,42 of a small increase in social functioning as a result of
community-based interventions (SMD=0.33, 95% CI 0.10–0.55,
P= 0.004, I 2 = 88%, n= 316), despite neither trial showing an
effect on clinical outcomes. The trials compared a package of
interventions combining psychotherapies (mainly psychoeducation
and family therapy) compared with either in-patient treatment
or standard out-patient treatment, with both groups receiving
medication. This finding was replicated in a third trial that could
not be included in the meta-analysis because of a lack of data,
which also showed a significant improvement in social functioning
at 12- and 18-month follow-up.32
There was not enough evidence to assess the effect of art
therapy or social skills training as only one study respectively
assessed these interventions.
Publication bias
Online Figs DS7 and 8 present the funnel plots to assess potential
publication bias for the primary meta-analyses. We performed a
visual inspection of the plots in line with recommendations not
to perform statistical tests of asymmetry where there are a small
number of trials or there is significant heterogeneity between
trials.43 Although a visual inspection of the plots shows them to
be somewhat asymmetrical, this asymmetry may have been caused
by heterogeneity in intervention type rather than publication bias,
as indicated by the large I 2 for the combined effect estimates.
Some asymmetry may also have been caused by the tendency in
this review for the poorer quality trials to show larger effects, as
documented elsewhere.44
Discussion
Main findings
A total of 11 depression trials from 5 countries and 13 schizo-
phrenia trials from 3 countries were included in this review.
Overall, the results show that different types of psychosocial
interventions are effective at improving social functioning in
people with depression and schizophrenia in LAMI countries.
For depression, there is strong evidence that stepped collaborative
care interventions, often delivered by non-specialists and comprising
structured pharmacotherapy, psychoeducation, adherence support
and in some cases structured psychotherapy have moderate effects
on improving patient social functioning up to 12 months from
start of treatment. There was also some evidence that IPT, often
delivered by non-specialists, is effective at improving social
functioning over a 12-month period. For schizophrenia, inter-
ventions demonstrated a strong effect, but the interpretation of
these findings is tempered by the risk of bias associated with seven
of the ten trials. The generalisability of these findings is also
restricted by the predominance of trials of hospital in-patients
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Fig. 3 Schizophrenia: main results (12-month follow-up).
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in China. However, there was good evidence from three high-quality
trials that a combination of structured psychological therapies (for
example psychoeducation, social skills training and IPT), delivered
in combination with antipsychotic medication, leads to large
improvements in patient social functioning compared with
medication alone.
A striking finding of this review is that improvements in social
functioning were maintained at long follow-up periods of over a
year. In contrast to clinical improvements that are often observed
early in the intervention, improvements in social functioning were
sometimes only evident at later stages (for example Li & Arthur33
and Pang et al42). It is likely that improvements in social functioning
happen more slowly and subsequently to clinical improvements
and that patients who recover symptomatically can be expected
to experience a positive change in social functioning. Indeed, in
the vast majority of included trials, concurrent improvements in
both clinical and social functioning were observed. However, an
intervention that improves social functioning may not necessarily
have an impact on clinical symptoms: notably, the two trials
assessing community care for schizophrenia demonstrated an
impact on social functioning even though the intervention had
no impact on clinical outcomes.41,42 This may be because these
interventions involved shifting the locus of care to the community
to promote re-integration following a hospital admission, rather
than specific treatments for clinical symptoms. Increased efforts
are needed to disentangle those aspects of interventions that are
effective at improving clinical symptoms and social functioning,
in order to ensure they are both cost-effective and acceptable to
patients and care providers.
Methodological limitations
We note some of the limitations of the evidence included in this
review that affect the strength of conclusions and generalisability
of the results, particularly to efforts to scale up services for people
with mental disorders in LAMI countries.45 For schizophrenia
there was an absence of evidence from high-quality trials and the
generalisabilty of the findings is limited by the over-representation
of trials from China conducted in populations of hospital patients.
Trials of task-shifted psychosocial interventions delivered in primary
care are urgently needed. In contrast, all but one of the trials
included in the depression meta-analysis were methodologically
strong.
Additional limitations of the evidence included in this review
include the short follow-up in a third of trials, potentially not
allowing sufficient time to detect improvements in functioning
in the intervention group. Although both the depression and
the schizophrenia reviews show that intervention effects were
sustained over greater than a 6- or 12-month period respectively,
the precision of this estimate is reduced by the smaller number of
trials included in this meta-analysis. Also, the measures of social
functioning used by the trials may have affected the results of
the review. Most of the scales used by the included trials do not
include the full range of social functioning domains listed in
online Table DS2, in particular parental functioning. Assessing
the impact that depression has on parental roles among women
is important46 as not only are they at a higher risk for depression,5
but maternal depression has been shown to affect child health47
and growth.48 Parental functioning was only measured in two of
the ten scales used by the included trials, leading to potential
underestimates of the effect of the intervention on social
functioning in these trials. Furthermore, few of the tools to
measure social functioning were developed or validated for the
setting in which they were used, with some exceptions18 and there
is a risk that contextually relevant outcomes, which may have the
biggest impact on reducing stigma49 were not captured. Lastly, no
trials were found that evaluated a number of types of psychosocial
interventions shown to be effective in high-income countries, such
as wellness promotion,50 vocational rehabilitation51 and cognitive
remediation.52,53 Trials in LAMI countries evaluating the effect of
these interventions on social functioning outcomes are needed.
On the other hand, the methods used for this review were
strong. We used a wide-ranging search strategy with no limitations
set on date, publication type or language. This resulted in the
identification of a substantial body of previously largely uncited
work from China that significantly adds to the body of knowledge
particularly on the effectiveness of schizophrenia interventions.
We conducted a meta-analysis of similar trials, using outcomes
measured at similar time points and with comparable control
groups to test the size of the effect of the interventions on social
functioning, and examined heterogeneity by study quality.
Implications
The results of this review have a number of implications for future
research.
(a) All trials of interventions for mental disorders in LAMI
countries should use locally validated social functioning
scales to measure social functioning outcomes in addition to
measuring clinical and economic outcomes.
(b) Trial participants should be followed up for a sufficiently long
time to detect changes in social functioning compared with
clinical symptoms. Minimum follow-up times of 6 months
for depression and 12 months for schizophrenia are
recommended.
(c) Trials (particularly for schizophrenia) should be conducted of
psychosocial interventions by non-specialist health workers, to
directly inform efforts to scale up mental health services.
(d) Trials are needed of other psychosocial interventions such as
wellness promotion, vocational rehabilitation and cognitive
remediation, which hold promise for delivering improvements
in social functioning but which have not yet been evaluated in
LAMI countries.
Developing interventions that improve social functioning is
important for a number of reasons. First, there is increasing
evidence that service users place greater value on improvements
in social functioning than improvements in clinical status54–56
and that impairments in social functioning are often a key factor
in an individual’s decision to seek care.3 Second, it has been
suggested that seeing individuals with mental disorders
successfully treated and return to socially productive roles has
the greatest impact on reducing stigma57 and may succeed where
concerted efforts at improving mental health literacy have failed.58
Ultimately, social functioning is seen as an increasingly important
factor for reducing the overall burden of mental disorders,
particularly for chronic or recurrent conditions such as
schizophrenia and depression that cause very high levels of
disability.59
This review provides strong evidence for depression and
weaker evidence for schizophrenia in support of the use of a range
of psychosocial interventions, with or without concurrent
pharmacological interventions5,6 in LAMI countries. Many of
the interventions included in the review were delivered by non-
specialists in collaborative and/or stepped-care delivery models
often in primary care or community settings. The scarcity of
specialist human resources in these settings60 indicates that these
packages of care should be delivered by non-specialists working
under the supervision of specialists, who provide capacity-
building, continued supervision and referral pathways to enhance
the effectiveness of these interventions.61 These findings therefore
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directly inform efforts such as the World Health Organization
(WHO) Mental Health Gap Action Programme56 to scale up
mental health services in LAMI countries. This review also
supports calls to monitor the social functioning of patients as part
of routine clinical practice3,46 in order to ensure that treatments
go beyond clinical effectiveness and meet the wider needs of
patients. Providing interventions that improve patient social
functioning will not only reduce the burden of mental disorders
by enabling people to fulfil a productive social role, but may also
be the most effective way to combat stigma.
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Appendix
Inclusion and exclusion criteria for review
Study population
Included: study conducted in LAMI country as defined by the World Bank.
Any age.
Excluded: study conducted in high-income country.
Condition of interest
Included: depressive disorders and schizophrenia.
Excluded: other mental disorders, for example substance misuse, bipolar
and anxiety disorders.
Intervention
Included: any psychosocial intervention (non-pharmacological) aimed at
improving the lives of people with mental health problems and their
families. This includes psychotherapy, social and collaborative care
interventions where a number of different interventions are combined.
Excluded: interventions not administered to the person with the mental
health problem or their families/carer (for example interventions for
healthcare staff).
Study design
Included: individual and cluster RCTs. Effectiveness trials with a placebo or
TAU control group.
Excluded: non-randomised intervention studies, case–control or cross-
sectional studies. Equivalence trials with an active control group.
Outcome
Included: social functioning measured using a validated tool.
Excluded: individual measures of social functioning such as marital status,
employment status or quality of social relationships. Quality of life
measures.
Meta-analysis
Included: study reports a quantitative estimate of the effect of the
intervention on the outcome suitable for combination in a meta-analysis.
Excluded: no quantitative estimate of effect suitable for combination in a
meta-analysis.
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